Introduction
β Cell failure (loss of β cell function and mass) is a hallmark of both type 1 and 2 diabetes (T1D/T2D). Over the past 20 years, little progress has been made in identifying efficient strategies to stop β cell failure. The further decline in β cell function during current therapies highlights the need for improved therapeutic approaches as well as better understanding of the molecular changes underlying functional β cell loss in diabetes. Apoptosis of insulin-producing β cells is the fundamental cause of T1D and a contributing factor to the reduced β cell mass in T2D (1) (2) (3) (4) . Given the varied and enigmatic nature of the causes of β cell failure, inhibition of apoptosis and/or enhancement of β cell regenerative capacity by augmenting β cell proliferation represent attractive therapeutic approaches to the treatment of diabetes (5) .
Identification of signaling molecules that regulate both β cell apoptosis and proliferation, together with an in-depth knowledge of their mechanisms of action is a prerequisite for the discovery of new drugs for β cell-directed therapies in diabetes. Characterization of signaling cascades such as PI3K-AKT, MAPK, and Wnt has particularly contributed to the understanding of β cell pathogenesis in diabetes (6) (7) (8) (9) (10) (11) (12) . A more recently discovered signal is the Hippo pathway that was proposed to regulate organ size. Initially defined in Drosophila, the conservation of this pathway in mammals has been firmly established, where it consists of the core kinase complexes mammalian sterile 20-like kinases (MST1/2) and large-tumor suppressors (LATS1/2), adaptor proteins (SAV1 for MST1/2 and MOB1 for LATS1/2), and downstream transcriptional coactivators (YAP and TAZ). MST1/2 kinases phosphorylate and activate LATS1/2 kinases. Active LATS1/2 phosphorylates YAP at serine 127 (S127) and provides the docking site for the 14-3-3 protein, which sequesters YAP in the cytoplasm and ultimately leads to ubiquitindependent degradation that thereby prevents YAP transcriptional activity (13) (14) (15) (16) . YAP acts mainly Loss of functional pancreatic β cells is a hallmark of both type 1 and 2 diabetes. Identifying the pathways that promote β cell proliferation and/or block β cell apoptosis is a potential strategy for diabetes therapy. The transcriptional coactivator Yes-associated protein (YAP), a major downstream effector of the Hippo signaling pathway, is a key regulator of organ size and tissue homeostasis by modulating cell proliferation and apoptosis. YAP is not expressed in mature primary human and mouse β cells. We aimed to identify whether reexpression of a constitutively active form of YAP promotes β cell proliferation/survival. Overexpression of YAP remarkably induced β cell proliferation in isolated human islets, while β cell function and functional identity genes were fully preserved. The transcription factor forkhead box M1 (FOXM1) was upregulated upon YAP overexpression and necessary for YAP-dependent β cell proliferation. YAP overexpression protected β cells from apoptosis triggered by multiple diabetic conditions. The small redox proteins thioredoxin-1 and thioredoxin-2 (Trx1/2) were upregulated by YAP; disruption of the Trx system revealed that Trx1/2 was required for the antiapoptotic action of YAP in insulin-producing β cells. Our data show the robust proproliferative and antiapoptotic function of YAP in pancreatic β cells. YAP reconstitution may represent a disease-modifying approach to restore a functional β cell mass in diabetes.
through TEA domain (TEAD) family transcription factors to promote the expression of target genes required for cell proliferation and survival. The loss of any component of the kinase core results in a YAP-dependent increase in proliferation and resistance to apoptosis in multiple tissues, suggesting Hippo as a powerful tool to regulate organ size (16) (17) (18) .
Targeting the Hippo signaling pathway has recently emerged as an attractive therapeutic strategy for treatment of various pathological disorders (19) (20) (21) (22) (23) (24) . Although previously studied in pancreas development (25) (26) (27) , little is known about the role of Hippo signaling components in the adult β cell in normal and disease states. We have recently identified MST1, the key core component of Hippo signaling, as a principal regulator of pancreatic β cell apoptosis and dysfunction in human and rodent β cells in vitro as well as in diabetic animal models in vivo (28, 29) . At prenatal developmental stages, pancreas proliferation and cell-type specification is regulated by Hippo signaling. As major downstream effectors, TEAD and its coactivator YAP play a crucial role in the expansion of pancreatic progenitors by controlling key pancreatic signaling mediators and transcription factors in the embryonic phase of pancreas development (27) . Consistently, YAP depletion is sufficient to block pancreatic progenitor cell proliferation (30) . However, convincing studies have revealed that YAP is not expressed in terminally differentiated mature primary human and mouse β cells. YAP expression decreases as pancreas development proceeds and eventually switches off in the mature endocrine but not in the exocrine cells (25, 26) ; this correlates with the extremely low rate of β cell proliferation and β cell quiescence. Thus, while YAP signals are disconnected from the core Hippo kinases in mature islets, MST1/2 and LATS1/2 are still expressed and are able to activate Hippo signaling in the absence of YAP, suggesting the presence of alternative Hippo downstream effector(s). Notably, lack of MST1 alone (28) or both MST1 and MST2 (26) is not sufficient to drive pancreatic β cells out of quiescence and induce β cell proliferation. The absence of YAP as a critical signaling element of the Hippo pathway may explain the lack of endocrine cell proliferation in this context. Conversely, pancreas-specific MST1/2 knockout is sufficient to increase ductal and acinar proliferation, due to aberrant YAP activity in the exocrine compartments (26) .
Since YAP has both antiapoptotic and proproliferative activity in other cell types, the reexpression of YAP may provide a strategy directed towards promoting β cell proliferation and protecting from stressinduced conditions relevant to diabetes. In this study, we aimed to identify whether reexpression of a constitutively active form of YAP promotes β cell proliferation in isolated human islets and whether such overexpression would also protect β cells from apoptosis under diabetic conditions.
Results
Overexpression of constitutively active YAP (YAP S127A ) promotes human β cell proliferation. Given the proproliferative function of YAP in other cell types, we asked whether reintroduction of the activated form of YAP is sufficient to drive β cell proliferation. Isolated human islets were infected with adenovirus expressing luciferase (Ad-Luc) as a control or Ad-YAP expressing activated YAP with a serine 127 to alanine substitution (YAP S127A ) that abolishes MST/LATS-mediated YAP inactivation and provides a constitutively active form of YAP (31) . YAP overexpression remarkably increased β cell proliferation in isolated primary human islets seen in multiple different organ donors by significantly increased Ki67-positive ( Figure 1 Gene expression profiling showed that YAP potently and coordinately initiates gene programs that promote cell-cycle activity and proliferation in different cell types (32, 33) . As many of these YAP-target genes are able to promote β cell proliferation, e.g., the transcription factor forkhead box M1 (FOXM1) (34) , their identification as regulators of YAP might provide a molecular explanation of how YAP induces β cell proliferation. To identify the downstream YAP effector and mediator of YAP-induced proliferation in β cells, we investigated expression levels of FOXM1. YAP overexpression significantly induced a 2-fold elevated FOXM1 mRNA expression in human islets ( Figure 2A ) together with an increase in FOXM1 protein ( Figure 2 , B and C) levels. To investigate the potential of FOXM1 as a mediator of YAP-induced β cell proliferation, we used a pharmacologic inhibitor of FOXM1 expression, thiostrepton (35, 36) . Thiostrepton fully blocked β cell proliferation in the Ad-YAP-infected human islets (Figure 2 , D-G), suggesting that increased FOXM1 is a crucial contributor of β cell proliferation in YAP-reconstituted β cells. Together, our data show that YAP robustly induced β cell proliferation in a FOXM1-dependent way.
Overexpression of constitutively active YAP does not alter β cell functional status. We then investigated whether YAP overexpression in human islets compromised their ability to secrete insulin in response to glucose in vitro. Glucose-stimulated insulin secretion (GSIS) assays in human islets infected with Ad-Luc or Ad-YAP showed that YAP-overexpressing islets maintained their insulin secretory capacity ( Figure 3 Despite the tendency of higher expression of some genes including Nkx6.1 in Ad-YAP-infected islets, statistical analysis of pooled quantification data from 4 different human islet donors shows no significant differences for all analyzed genes except for MafA ( Figure 3C ; P < 0.05). MafA is a wellknown regulator of insulin gene expression and is required for β cell maturation (37, 38) , but its modest upregulation upon YAP overexpression did not alter insulin mRNA levels in our study. This is not surprising, as insulin gene expression is known to be regulated by a complex transcriptional network involving multiple transcription factors such as PDX1, NeuroD1, and MafA (39) . Thus, the slight upregulation of one (MafA) -while 2 other critical transcription factors were unchanged (NeuroD1 and PDX1) -was insufficient to enhance insulin mRNA transcription.
Overexpression of constitutively active YAP protects β cells from apoptosis under diabetic conditions. The important role of YAP-associated signaling in suppressing apoptosis led us to hypothesize that YAP activation would also protect β cells from apoptosis under diabetic conditions. INS-1E cells were transfected either with YAP or control GFP plasmid and then exposed chronically to increased glucose concentrations (glucotoxicity), its combination with the free fatty acid palmitate (glucolipotoxicity), the mixture of proinflammatory cytokines interleukin-1β (IL-1β) and interferon γ (IFN-γ; cytokine toxicity), as well as acute exposure to hydrogen peroxide (H 2 O 2 , an in vitro model of oxidative stress). Overexpression of YAP markedly reduced glucose-, glucose/palmitate-, cytokine-, as well as H 2 O 2 -induced apoptosis as represented by decreased caspase-3 and PARP cleavage (Figure 4 , A-F). Glucotoxicity and glucolipotoxicity as well as proinflammatory cytokines reduced the level of transfected YAP, which inversely correlated with caspase-3 and PARP cleavage ( Figure 4 , A and C). In order to further corroborate the antiapoptotic impact of reexpressed YAP in diabetes, we used an in vitro model of human islets exposed to a diabetogenic milieu of the proinflammatory cytokines or glucolipotoxicity. YAP was overexpressed by adenovirus-mediated infection of human islets isolated from nondiabetic organ donors. Apoptosis triggered by proinflammatory cytokines as well as by the mixture of high glucose/palmitate was counteracted by YAP overexpression in isolated human islets, demonstrated independently by 4 human islet isolations (representative Figures shown from 3 isolations; Figure 5 , A and C). Our data show that YAP overexpression significantly blocked caspase-3 activation in human islets under diabetic conditions ( Figure 5 , B and D). These data show that YAP functions as a prosurvival signal to ameliorate the proapoptotic effect of diabetic conditions in the β cells.
The antiapoptotic effect of YAP is mediated by redox proteins Trx1/2. Since oxidative stress is an underlying mechanism of β cell destruction in diabetes (40) (41) (42) and ROS-associated signaling is regulated by YAP in other cell types (43, 44) , we tested whether YAP overexpression would change expression of ROS-related genes. To identify YAP-regulated genes involved in the antioxidant system, we analyzed a panel of 25 ROS-related genes in the constitutively active YAP mutant-expressing or GFP-control-expressing INS-1E cells (data not shown). Our gene expression profiling revealed the components of the redox thioredoxin system including thioredoxin-1 (Trx1) and thioredoxin-2 (Trx2) as the most significantly upregulated genes in YAP-overexpressing β cells ( Figure 6A ). To further substantiate YAP-dependent regulation of Trx1/2, we measured the expression of Trx1/2 genes in isolated human islets. RT-PCR analysis showed that expression of Trx1 and Trx2 was higher in YAP-overexpressing human islets, compared with Ad-Luc controls ( Figure 6B ). Consistently, higher levels of Trx1 and Trx2 proteins were detected by Western blotting in YAP-overexpressing INS-1E cells ( Figure 6 , C and D) and human islets ( Figure 6 , E and F), confirming functional upregulation of Trx1/2 upon reexpression of YAP. Based on these observations, we sought to determine whether Trx1/2 is required for the prosurvival effect of YAP in β cells under diabetic conditions. Disruption of Trx1/2 redox equilibrium by an irreversible inhibitor of Trx1, 1-methylpropyl 2-imidazolyl disulfide (PX-12), or a chemical inhibitor of thioredoxin reductase (TrxR), auranofin, not only diminished the antiapoptotic effect of YAP but also highly exacerbated high-glucose-induced apoptosis as represented by upregulation of caspase-3 and PARP cleavage ( Figure 6G ). To further confirm that Trx1/2 mediates the effect of YAP on apoptosis inhibition, Trx1 and Trx2 were depleted by short interfering RNA (siRNA) in INS-1E cells. Loss of Trx1 or Trx2 potentiated glucose-induced apoptosis in the GFP control group as represented by cleavage of caspase-3 and PARP. The extent of induction (magnitude of amplification above basal high-glucose-treated and scrambled control siRNA-transfected cells, for both GFP-and YAPtransfected groups) was much lower in the YAP-transfected group; this correlates with remaining YAP present in Trx1-or Trx2-depleted cells ( Figure 6H ). Notably, Trx1/2 silencing reduced protein levels of exogenously expressed YAP; this correlated with massive induction of apoptosis and suggests the importance of cellular redox states for maintaining YAP protein levels ( Figure 6H ). Our data show a prosurvival mechanism of YAP action via Trx1/2 signaling and the functional significance of Trx1/2 as upstream effectors of YAP protein levels in the β cell.
Discussion
Diabetes results from an insufficient functional β cell mass. The identification of signaling molecules that foster β cell mass regeneration by simultaneous blockade of β cell apoptosis and augmentation of β cell proliferation would be highly important and most suitable for a β cell-directed therapy in diabetes. As regenerating β cells are similarly susceptible to apoptotic attack in general and even further under diabetes-relevant stressors such as inflammation and glucolipotoxicity, targets that induce β cell proliferation should ideally be combined with apoptosis-blocking strategies in order to maintain a functional β cell mass and thus to correct impaired glucose homeostasis. Here we show that the Hippo terminal effector YAP not only induced adult human β cell proliferation but also protected β cells from apoptosis induced by a diabetic milieu, suggesting that YAP is a potent factor involved in both β cell replication and survival.
Stimulating cell cycle reentry and proliferation of adult human β cells has proven to be very difficult and challenging (45) (46) (47) (48) (49) . Processes that mediate the postnatal and age-dependent decline in proliferative and regenerative capacity of β cells remain largely unknown (50) (51) (52) (53) . Hypothetically, the loss of YAP signals right at the onset of pancreatic neurogenin-3 (Ngn3) expression and development of the endocrine pancreas (54) would reduce the ability of adult β cells to reenter the cell cycle and thus limit the regenerative potential of adult β cells. Overexpression of the YAP canonical target gene encoding connective tissue growth factor (CTGF) in a β cell regeneration model of partial pancreatectomy or treatment of human islets with recombinant human CTGF induces β cell proliferation (55) , demonstrating that a YAP target acts directly on islets to promote β cell replication. Recent research has provided further insights into the importance of YAP in tissue regeneration. A functional consequence of the experimental elevation of YAP activity is the entry of nondividing or hardly dividing cells into the cell cycle, seen in both liver (56, 57) and heart (31, 58, 59) . Together, these lines of evidence show that YAP transcriptional activity is enhanced and required for initiating cell proliferation and for complete tissue recovery in response to different types of injury. Hence, transient elevation of YAP activity might be useful for β cells that normally do not undergo proliferation and for augmenting the regenerative capability of damaged β cells in the context of diabetes.
Functional interaction of YAP with many proliferation-associated signaling networks contributes to its growth-promoting activity and is related to multiple physiological processes such as the regulation of cell cycle and proliferation (19) (20) (21) (22) (23) (24) 32) . YAP-dependent human β cell proliferation was accompanied and regulated by increased expression of transcription factor FOXM1. FOXM1 is a master regulator of cellular proliferation by controlling G1/S transition, S-phase progression, as well as G2/M transition. Gannon's lab pioneered establishing the critical role of FOXM1 in postnatal β cell proliferation and mass expansion under conditions of increased β cell stress and demand in vivo (60, 61) . Mice with pancreasspecific deletion of FOXM1 showed progressive β cell loss and overt diabetes (62) . Conversely, FOXM1 overexpression alone is sufficient to induce β cell proliferation in mouse and human primary islets, highlighting the central role of FOXM1 in β cell proliferation (34) . Consistent with the YAP-dependent FOXM1 upregulation in our study, Mizuno et al. reported that the YAP-TEAD complex directly binds to the FOXM1 promoter and induces transcriptional upregulation of FOXM1 in a cancer model of malignant mesothelioma (32) . As YAP is a potential oncoprotein, interventions to increase β cell proliferation raise concerns about the possibility of neoplastic growth. Thus, YAP-based therapeutic approaches to restore lost or damaged β cells should be combined with strategies designed to limit YAP overactivation and uncontrolled cell proliferation. The acute and targeted manipulation of YAP may keep its levels physiological, tightly controlled, and ideally sufficient for modest β cell proliferation, mass expansion, and restoration of glucose homeostasis. Our data show that overexpression of the constitutively active form of YAP effectively diminished β cell death triggered by multiple diabetic conditions in vitro including proinflammatory cytokines, gluco-and lipotoxicity, and oxidative stress. The prosurvival effect of YAP reexpression in stressed β cells induced by different diabetic stimuli raises the possibility that the antiapoptotic outcome of YAP comes from coordinating and regulating a common antiapoptotic gene expression program that promotes β cell protection. By gene expression profiling and subsequent protein analysis, we demonstrate that YAP induced profound upregulation of Trx system components in β cells. In line with our data, 2 independent studies showed YAP-induced upregulation of Trx components either through liver-specific deletion of MST1/2 and subsequent YAP activation or direct activation of YAP (44, 63) . The Trx system consists of NADPH, TrxR, and Trx and is a redox-sensitive signaling system that protects cells from oxidative stress. It has emerged as a key element linking redox regulation to the pathogenesis of several diseases (64) . Oxidative stress has been recognized as one of the common underlying mechanisms of β cell failure in the pathogenesis of both types of diabetes (40) (41) (42) . In vivo β cell-specific overexpression of Trx1 protects mice from development of diabetes in both T1D and T2D rodent models, demonstrating the efficacy of Trx1 to halt the progressive β cell demise (65, 66) . Trx1 also functions as the molecular sensor for the redox-dependent regulation of MST1 activity; Trx1 inhibits stress-induced MST1 activation by directly compromising MST1 homodimerization and autophosphorylation (67) . MST1 hyperactivity is a major underlying mechanism of β cell apoptosis and the consequent decrease in β cell mass in the diabetic state (28) . Thus, Trx1 might function as a YAP-dependent molecular signal to turn off the prodiabetic milieu-induced MST1 activation and subsequent apoptosis as part of compensatory negative-feedback loop within the Hippo signaling. Further detailed investigation is required to support such a possibility. As highlighted, YAP overexpression induced Trx1/2 at mRNA and protein levels in both human islets and INS-1E cells in control ( Figure  6 , A-F) and diabetic states ( Figure 6H ). On the other hand, Trx1/2 silencing itself reduced exogenously expressed YAP protein ( Figure 6H ); this suggests that the Trx1/2 system -or the cellular redox state in general -controls the level of YAP. Thus, shifting the cellular redox environment to pro-oxidant states by loss of Trx1 or Trx2 promotes YAP degradation and reverses the prosurvival effect of YAP. Together, YAPinduced Trx1/2 upregulation and Trx1/2-mediated YAP regulation by MST1 (as speculated above) form complex regulatory signaling loops (see scheme in Figure 7 ), which control redox state and cell survival.
In full agreement with our study, George et al. (54) also reported the robust induction of human β cell proliferation by YAP activation with preservation of insulin-secretory function. In this study, Ngn3dependent specification during development of the endocrine pancreas is sufficient for loss of YAP and decreased proliferation. Also, mechanistic (or mammalian) target of rapamycin (mTOR) signaling was proposed as an underlying mechanism of YAP-induced β cell proliferation (54) . We have not directly assessed whether mTOR activity is regulated in YAP-overexpressing human islets, but FOXM1 might function as a part of mTOR-associated signaling in YAP-hyperactivated cells. This link between mTOR and FOXM1 was previously identified for epidermal growth factor receptor (EGFR) signaling-mediated β cell proliferation in response to overnutrition (68) . Consistent with George et al. (54) , most of the BrdU-and insulin-positive or Ki67-and insulin-positive cells were YAP positive, suggesting mostly a cell-autonomous proproliferative action of YAP. However, a non-cell autonomous effect of YAP overexpression cannot entirely be ruled out. For example, CTGF, an established canonical YAP target gene, is highly upregulated upon YAP overexpression in islets, as shown by George et al. (54) as well as in our study in human islets (data not shown). CTGF is a secreted growth factor that is capable of promoting human β cell proliferation and β cell regeneration in a model of partial pancreatectomy (55) . Thus, highly produced CTGF and/or other uncharacterized secreted proteins upon YAP reconstitution may trigger proliferation in YAP-negative cells by a paracrine mechanism. Further studies are required to reveal such a possibility.
Conclusion. Insufficient and dysfunctional β cell mass is a central feature of both types of diabetes. Thus, strategies aiming to regenerate pancreatic β cell mass by blocking β cell apoptosis as well as promoting proliferation are urgently needed. Considering the remarkable antiapoptotic and proproliferative output of YAP reexpression in β cells, manipulation of YAP may serve as a therapeutic tool for restoring functional β cell mass in diabetes. To warrant this, further mechanistic studies as well as the in vivo preclinical assessment of efficacy and side effects of YAP overexpression in β cells are required. Here, owing to its oncogenic potential, YAP activity must be strictly regulated.
Methods
Cell culture, treatment, and islet isolation. Human islets were isolated from pancreases of healthy organ donors at the University of Chicago and at ProdoLabs and cultured on extracellular matrix-coated (ECM-coated) dishes (Novamed) as described previously (69) . The clonal rat β cell line INS-1E was provided by Claes Wollheim, the University of Geneva, Geneva, Switzerland and the University of Lund, Lund, Sweden. Human islets were cultured in complete CMRL-1066 (Invitrogen) medium at 5.5 mM glucose and INS-1E cells in complete RPMI-1640 (Invitrogen) medium at 11.1 mM glucose as described previously (28) . Islets and INS-1E were exposed to complex diabetogenic conditions (28) . In some experiments, cells were additionally cultured with 10 μM FOXM1 inhibitor thiostrepton (Calbiochem), 1-5 μM selective Trx1/2 inhibitor PX-12, and 0.1-1 μM TrxR inhibitor auranofin (both Cayman Chemical). BrdU was added to the culture media at 10 μM for 2 days to label proliferating cells.
Transfections. To knock down Trx1 and Trx2 in INS-1E cells, SMARTpool technology from Dharmacon was used. A mix of ON-TARGETplus siRNAs directed against the following sequences: in rat Txn1, GCAAAAUGAUCAAGCCCUU, GGAUGUUGCUGCAGACUGU, AGCUUGUGGUAGUG-GACUU, CCUUGAAGUAGGACGUGGAU; and rat Txn2, GAUCCUAGGACCUCGGUUA, UAGC-CAAACAGCACGGGAA, CAAAGUGGACAUUGACGAU, GAAGCUAAUUGGCUGACAA (100 nM, Dharmacon) was transiently transfected into INS-1E cells as described previously (28) . GFP and YAP (pCMV-flag YAP S127A , a gift from Kunliang Guan [Addgene plasmid number 27370]) plasmids were used to overexpress these proteins in INS-1E cells.
Glucose-stimulated insulin secretion. Glucose-stimulated insulin secretion in human islets was performed as described previously (28) .
Immunohistochemistry. Human islets cultured on ECM dishes were fixed, permeabilized, blocked, and incubated overnight at 4°C with anti-human Ki67 (catalog 08-1192; Invitrogen), mouse anti-BrdU (catalog NA61; Calbiochem), rabbit anti-Flag (catalog F7425; Sigma-Aldrich) and anti-insulin (catalog A0546; Dako) antibodies followed by fluorescein isothiocyanate (FITC)-, Cy3-, or AMCA-conjugated secondary antibodies (Jackson ImmunoResearch Laboratories). Slides were mounted with Vectashield with 4′,6-diamidino-2-phenylindole (DAPI; Vector Labs). Fluorescence was analyzed using a Nikon MEA53200 microscope and images were acquired using NIS-Elements software (Nikon).
Western blot analysis. Western blotting was performed as described previously (28) . Membranes were incubated overnight at 4°C with rabbit anti-cleaved caspase-3 (catalog 9664), rabbit anti-Trx1 (catalog 2429), rabbit anti-Trx2 (catalog 14907), rabbit anti-YAP (catalog 4912), rabbit anti-PARP (catalog 9532), rabbit anti-cleaved PARP (rat specific, catalog 9545), rabbit anti-tubulin (catalog 2146), rabbit anti-GAP-DH (catalog 2118), rabbit anti-β-actin (catalog 4967) (all Cell Signaling Technology), rabbit anti-FOXM1 (catalog ab55006; Abcam), and rabbit anti-Flag (catalog F7425; Sigma-Aldrich), followed by horseradish peroxidase-linked anti-rabbit IgG (Jackson ImmunoResearch Laboratories). Membranes were developed using a chemiluminescence assay system (Pierce) and analyzed using DocIT LS image acquisition 6.6a (UVP BioImaging Systems). Densitometric analysis of the immunoblots was performed using Vision Works LS Image Acquisition and Analysis software Version 6.8 (UVP BioImaging Systems).
